EP0785992A4 - Conditional transformation of genetically engineered cells - Google Patents

Conditional transformation of genetically engineered cells

Info

Publication number
EP0785992A4
EP0785992A4 EP95937629A EP95937629A EP0785992A4 EP 0785992 A4 EP0785992 A4 EP 0785992A4 EP 95937629 A EP95937629 A EP 95937629A EP 95937629 A EP95937629 A EP 95937629A EP 0785992 A4 EP0785992 A4 EP 0785992A4
Authority
EP
European Patent Office
Prior art keywords
genetically engineered
engineered cells
conditional transformation
conditional
transformation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95937629A
Other languages
German (de)
French (fr)
Other versions
EP0785992A1 (en
Inventor
Gerald R Crabtree
David Spencer
Leslie Holsinger
Isabella Graef
Stuart Schreiber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Leland Stanford Junior University
Original Assignee
Harvard University
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University, Leland Stanford Junior University filed Critical Harvard University
Publication of EP0785992A1 publication Critical patent/EP0785992A1/en
Publication of EP0785992A4 publication Critical patent/EP0785992A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C07K2319/715—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16 containing a domain for ligand dependent transcriptional activation, e.g. containing a steroid receptor domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/72—Fusion polypeptide containing domain for protein-protein interaction containing SH2 domain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
EP95937629A 1994-10-25 1995-10-25 Conditional transformation of genetically engineered cells Withdrawn EP0785992A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32893194A 1994-10-25 1994-10-25
US328931 1994-10-25
PCT/US1995/013776 WO1996012796A1 (en) 1994-10-25 1995-10-25 Conditional transformation of genetically engineered cells

Publications (2)

Publication Number Publication Date
EP0785992A1 EP0785992A1 (en) 1997-07-30
EP0785992A4 true EP0785992A4 (en) 1999-12-22

Family

ID=23283095

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95937629A Withdrawn EP0785992A4 (en) 1994-10-25 1995-10-25 Conditional transformation of genetically engineered cells

Country Status (4)

Country Link
EP (1) EP0785992A4 (en)
JP (1) JPH11511643A (en)
AU (1) AU3968595A (en)
WO (1) WO1996012796A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999034836A1 (en) * 1998-01-08 1999-07-15 University Of Washington Methods of controlling cell differentiation and growth using a fusion protein and a drug
ATE473759T1 (en) 1998-05-22 2010-07-15 Univ Leland Stanford Junior BIFUNCTIONAL MOLECULES AND THERAPIES BASED THERAPIES.
US6887842B1 (en) 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
AU2044001A (en) 1999-11-19 2001-05-30 Board Of Trustees Of The Leland Stanford Junior University Targeted bifunctional molecules and therapies based thereon
US7220552B1 (en) 1999-11-19 2007-05-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and their use in the disruption of protein-protein interactions
KR100702373B1 (en) 2001-06-22 2007-04-02 에프. 호프만-라 로슈 아게 Soluble Complex Containing Retroviral Surface Glycoprotein
EP2557164A1 (en) 2003-02-18 2013-02-13 Kevin M. Slawin Induced activation in dendritic cells
AU2007310946B2 (en) 2006-10-19 2014-06-05 Baylor College Of Medicine Generating an immune response by inducing CD40 and pattern recognition receptors
DK2331680T3 (en) 2008-09-22 2017-08-21 Baylor College Medicine Methods and Compositions for Generating an Immune Response by Induction of CD-40 as well as Pattern Recognition Receptor Adapters
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
US10634668B2 (en) 2012-09-13 2020-04-28 Takara Bio Usa, Inc. Modifiable chemical inducers of proximity and methods of using the same
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
AU2014236726A1 (en) 2013-03-14 2015-09-17 Bellicum Pharmaceuticals, Inc. Methods for controlling T cell proliferation
JP6467406B2 (en) 2013-06-05 2019-02-13 ベリカム ファーマシューティカルズ， インコーポレイテッド Methods for inducing partial apoptosis using caspase polypeptides
EP4491726A3 (en) 2013-06-11 2025-03-05 Takara Bio USA, Inc. Protein enriched microvesicles and methods of making and using the same
JP6772063B2 (en) 2014-02-14 2020-10-21 ベリカム ファーマシューティカルズ， インコーポレイテッド Methods for activating cells using inducible chimeric polypeptides
WO2016036746A1 (en) 2014-09-02 2016-03-10 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
US10189880B2 (en) 2014-11-03 2019-01-29 Leiden University Medical Center T cell receptors directed against Bob1 and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023550A2 (en) * 1992-05-18 1993-11-25 Genentech, Inc. Activation of oligomerizing receptors by using fused receptor ligands
WO1994018317A1 (en) * 1993-02-12 1994-08-18 The Board Of Trustees Of The Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
WO1995002684A1 (en) * 1993-07-16 1995-01-26 The Board Of Trustees Of The Leland Stanford Junior University Regulated apoptosis
WO1996006111A1 (en) * 1994-08-18 1996-02-29 Ariad Gene Therapeutics, Inc. Regulatable elimination of gene expression, gene product function and engineered host cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023550A2 (en) * 1992-05-18 1993-11-25 Genentech, Inc. Activation of oligomerizing receptors by using fused receptor ligands
WO1994018317A1 (en) * 1993-02-12 1994-08-18 The Board Of Trustees Of The Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
WO1995002684A1 (en) * 1993-07-16 1995-01-26 The Board Of Trustees Of The Leland Stanford Junior University Regulated apoptosis
WO1996006111A1 (en) * 1994-08-18 1996-02-29 Ariad Gene Therapeutics, Inc. Regulatable elimination of gene expression, gene product function and engineered host cells

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ARONHEIM A ET AL: "Membrane targeting of the nucleotide exchange factor Sos is sufficient for activating the ras signaling pathway", CELL, vol. 78, 23 September 1994 (1994-09-23), NA US, pages 949 - 961, XP002117493 *
HOLSINGER L J ET AL: "Signal transduction in T lymphocytes using a conditional allele of Sos.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1995 OCT 10) 92 (21) 9810-4., XP002117491 *
KOLANUS, WALDEMAR ET AL: "T cell activation by clustered tyrosine kinases", CELL (CAMBRIDGE, MASS.) ( 1993 ), 74(1), 171-83, XP002117494 *
PRUSCHY M N ET AL: "Mechanistic studies of a signaling pathway activated by the organic dimerizer FK1012.", CHEMISTRY AND BIOLOGY, (1994 NOV) 1 (3) 163-72., XP002117492 *
See also references of WO9612796A1 *
SPENCER D M ET AL: "A general strategy for producing conditional alleles of Src-like tyrosine kinases.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1995 OCT 10) 92 (21) 9805-9., XP002117490 *

Also Published As

Publication number Publication date
AU3968595A (en) 1996-05-15
JPH11511643A (en) 1999-10-12
EP0785992A1 (en) 1997-07-30
WO1996012796A1 (en) 1996-05-02

Similar Documents

Publication Publication Date Title
EP0785992A4 (en) Conditional transformation of genetically engineered cells
EP0797454A4 (en) Improved adenoviral vectors and producer cells
HU9500264D0 (en) An improved method of agrobactenium-mediated transformation of cultvred soyhean cells
GB9310545D0 (en) Power coupling
PL340677A1 (en) Wind-propelled power plant
GB9204583D0 (en) Recombinant plant enzyme
AU3491195A (en) Genetically engineered cells that produce dopamine
ZA984681B (en) Plant transformation methods
AU3243595A (en) Genetically engineered swine cells
GB9809178D0 (en) Nuclear reprogramming of somatic cells
PL334476A1 (en) Reactor
AU2682895A (en) EG Cells of Ungulates
GB2317170B (en) Sequential batch reactor
IL113438A0 (en) Compositions and methods for cell transformation
PL357156A1 (en) Defoliation and minimization of plant regrowth following defoliation
IL114688A0 (en) Vectors and transformed host cells
GB2309986B (en) Structure of interlocking members
ZA975120B (en) Floating power plant
GB9619633D0 (en) Recombinant plant cells
TW306310U (en) Improved structure of car-assembly type robot
GB9207276D0 (en) Modified cells
AU7464494A (en) Xenogeneic scid model
ZA946535B (en) Stabilized enzyme solution and detergent prepared therefrom
GB9317179D0 (en) Harnessing of animals
GB9714873D0 (en) Novel process and compound

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970523

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19991105

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20010104